-
1 Comment
Genus plc is currently in a long term uptrend where the price is trading 11.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.6.
Genus plc's total revenue sank by 0.0% to $135M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $12M since the same quarter in the previous year.
Finally, its free cash flow grew by 120.0% to $14M since the same quarter in the previous year.
Based on the above factors, Genus plc gets an overall score of 3/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | GB0002074580 |
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | 1B |
---|---|
Beta | 0.6 |
PE Ratio | None |
Target Price | None |
Dividend Yield | 2.1% |
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. Further, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GBE.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025